Anixa Biosciences, Inc.
Anixa Biosciences, Inc. (ANIX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ANIX · as of Sep 30, 2025
Ownership Breakdown
67
Institutional Holders
$17.92M
Total Inst. Value
▲ $275,475 vs Q2
33.53M
Shares Outstanding
freeFloat 94.62%
5.43M
13F Shares Held
▲ 80,475 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ANIX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 1.42M | 4.38% | 4.38% | $4.69B | Nov 7, 2025 | ▲ 29.4K |
D.A. DAVIDSON & CO. pharmaceutical preparations | 614.3K | 1.89% | 1.89% | $2.03B | Oct 22, 2025 | — held |
LAIRD NORTON TRUST COMPANY, LLC pharmaceutical preparations | 597.2K | 1.84% | 1.84% | $1.97B | Nov 14, 2025 | ▼ 20.0K |
UBS GROUP AG pharmaceutical preparations | 474.5K | 1.46% | 1.46% | $1.57B | Nov 13, 2025 | ▼ 30.8K |
MISSION WEALTH MANAGEMENT, LP pharmaceutical preparations | 356.2K | 1.10% | 1.10% | $1.18B | Nov 4, 2025 | ▼ 13.4K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 343.6K | 1.06% | 1.06% | $1.13B | Nov 12, 2025 | ▲ 808 |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 214.0K | 65.88% | 65.88% | $706.05M | Feb 3, 2026 | ▲ 3.6K |
BLACKROCK, INC. pharmaceutical preparations | 161.0K | 49.58% | 49.58% | $531.37M | Nov 12, 2025 | ▲ 1.6K |
STATE STREET CORP pharmaceutical preparations | 120.5K | 37.10% | 37.10% | $397.65M | Nov 14, 2025 | — held |
CITADEL ADVISORS LLC pharmaceutical preparations | 96.0K | 29.56% | 29.56% | $316.83M | Nov 14, 2025 | ▲ 25.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
16
Increased
+234.2K shares7
New Positions
first time holders6
Decreased
−83.9K shares0
Sold Out
fully exitedNet shares change (top 50)
+150.3K
+234.2K / −83.9K
Net new holders
+17
7 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ANIX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Baskies Arnold M director | Jan 28, 2026 | Purchase | 10,000 | $3.04 | $30.4K | 135.0K | Form 4 ↗ |
Titterton Lewis H jr director | Jan 5, 2026 | Award | 25,000 | $3.18 | $79.5K | 25.0K | Form 4 ↗ |
KUMAR AMIT Chief Executive Officer | Jan 5, 2026 | Award | 350,000 | $3.18 | $1.11M | 350.0K | Form 4 ↗ |
Gottschalk Emily director | Jan 5, 2026 | Award | 25,000 | $3.18 | $79.5K | 25.0K | Form 4 ↗ |
Catelani Michael President, COO & CFO | Jan 5, 2026 | Award | 175,000 | $3.18 | $556.5K | 175.0K | Form 4 ↗ |
Baskies Arnold M director | Jan 5, 2026 | Award | 25,000 | $3.18 | $79.5K | 25.0K | Form 4 ↗ |
KUMAR AMIT Chief Executive Officer | Oct 30, 2025 | Tax Withhold | 169,439 | $4.06 | $687.9K | 610.5K | Form 4 ↗ |
Titterton Lewis H jr director | Jul 31, 2025 | Purchase | 10,000 | $3.08 | $30.8K | 953.3K | Form 4 ↗ |
KUMAR AMIT Chief Executive Officer | Jul 30, 2025 | Purchase | 5,000 | $3.16 | $15.8K | 579.9K | Form 4 ↗ |
Baskies Arnold M director | Jul 18, 2025 | Purchase | 5,000 | $3.39 | $16.9K | 125.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Anixa Biosciences, Inc. (ANIX) is primarily owned by institutional investors, who hold approximately 16.2% of total shares outstanding. Company insiders own approximately 5.38%, while retail and public investors account for the remaining 78.42%.
The largest institutional shareholder of Anixa Biosciences, Inc. is VANGUARD GROUP INC, holding approximately 1.42 million shares — equal to 4.38% of outstanding shares — as of September 30, 2025.
A total of 67 institutional investors currently hold ANIX stock, with a combined institutional value of approximately $17,923,919 as of the most recent 13F filing period.
Frequently asked questions
ANIX ownershipAnixa Biosciences, Inc. (ANIX) is primarily owned by institutional investors, who hold approximately 16.2% of shares. The largest shareholder is VANGUARD GROUP INC with a 4.38% stake. Company insiders hold 5.38%. Data sourced from SEC Form 13F as of September 30, 2025.